{"id":"W2588138906","doi":"10.1093/ofid/ofw195.06","title":"Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients With Multidrug-Resistant Human Immunodeficiency Virus-1 Infection","year":2016,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Human immunodeficiency virus (HIV); Virology; Multiple drug resistance; Immunology; Pediatrics; Internal medicine; Drug resistance; Clinical trial; Microbiology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003684072,0.001557032,0.00201634,0.0004056088,0.0006300846,0.0008509175,0.0007014641,0.000912739,0.002194829],"category_scores_gemma":[0.001921273,0.0006253088,0.001417076,0.0003163771,0.0008910682,0.0007607109,0.0003644497,0.002380107,0.0004928894],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005795832,"about_ca_system_score_gemma":0.001308429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005622357,"about_ca_topic_score_gemma":0.001176147,"domain_scores_codex":[0.9987313,0.0007647145,0.00006604559,0.0001351747,0.0001305232,0.0001721819],"domain_scores_gemma":[0.9980962,0.0003528865,0.0004625755,0.0001651464,0.0001519659,0.0007712875],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8097773,0.08178391,0.01985916,0.0005529919,0.001802169,0.0003118165,0.0003318517,0.001483234,0.03484195,0.0001387533,0.002264887,0.04685196],"study_design_scores_gemma":[0.3537514,0.5825799,0.05540622,0.00004514743,0.0008379698,0.0002954708,0.00007169709,0.001342244,0.00383643,0.0001347209,0.00165425,0.00004444994],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943159,0.001135078,0.0003952157,0.0001549812,0.00003515384,0.002223437,0.0005796743,0.00003563579,0.001124845],"genre_scores_gemma":[0.9920672,0.0009179125,0.001368727,0.0005933931,0.000138541,0.002864423,0.001052051,0.00002098701,0.0009769105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003684072,"threshold_uncertainty_score":0.01948345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01850527196294311,"score_gpt":0.3390952722038267,"score_spread":0.3205900002408836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}